BR112019018966A2 - analógicos da deutetrabenazina, sua preparação e uso - Google Patents

analógicos da deutetrabenazina, sua preparação e uso Download PDF

Info

Publication number
BR112019018966A2
BR112019018966A2 BR112019018966-1A BR112019018966A BR112019018966A2 BR 112019018966 A2 BR112019018966 A2 BR 112019018966A2 BR 112019018966 A BR112019018966 A BR 112019018966A BR 112019018966 A2 BR112019018966 A2 BR 112019018966A2
Authority
BR
Brazil
Prior art keywords
deutetrabenazine
compound
concentration
area
pharmaceutical composition
Prior art date
Application number
BR112019018966-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Kerr Jim
Zhang Chengzi
Original Assignee
Auspex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals, Inc. filed Critical Auspex Pharmaceuticals, Inc.
Publication of BR112019018966A2 publication Critical patent/BR112019018966A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pens And Brushes (AREA)
  • Machine Translation (AREA)
BR112019018966-1A 2017-03-15 2018-03-15 analógicos da deutetrabenazina, sua preparação e uso BR112019018966A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
US62/471,484 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use

Publications (1)

Publication Number Publication Date
BR112019018966A2 true BR112019018966A2 (pt) 2020-04-22

Family

ID=61873991

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019018966-1A BR112019018966A2 (pt) 2017-03-15 2018-03-15 analógicos da deutetrabenazina, sua preparação e uso

Country Status (20)

Country Link
US (4) US11813232B2 (https=)
EP (1) EP3596077A1 (https=)
JP (3) JP7608050B2 (https=)
KR (2) KR20200003791A (https=)
CN (1) CN110709398A (https=)
AR (1) AR111182A1 (https=)
AU (2) AU2018236336B2 (https=)
BR (1) BR112019018966A2 (https=)
CA (1) CA3056612A1 (https=)
CL (1) CL2019002629A1 (https=)
CO (1) CO2019011271A2 (https=)
EA (1) EA201992168A1 (https=)
IL (1) IL269132A (https=)
MX (1) MX2019010913A (https=)
PE (1) PE20191819A1 (https=)
SG (1) SG11201908477QA (https=)
TW (1) TWI772382B (https=)
UA (1) UA127052C2 (https=)
WO (1) WO2018170214A1 (https=)
ZA (1) ZA201906326B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso
KR20210114946A (ko) 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US11311488B2 (en) 2020-06-10 2022-04-26 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
CA2972242A1 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
EP4345100A3 (en) * 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2015084622A1 (en) * 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso

Also Published As

Publication number Publication date
KR20200003791A (ko) 2020-01-10
JP2024050724A (ja) 2024-04-10
JP7608050B2 (ja) 2025-01-06
US11179386B2 (en) 2021-11-23
CN110709398A (zh) 2020-01-17
TW201840317A (zh) 2018-11-16
IL269132A (en) 2019-11-28
CA3056612A1 (en) 2018-09-20
JP2023010754A (ja) 2023-01-20
AU2018236336B2 (en) 2022-02-24
JP7631572B2 (ja) 2025-02-18
SG11201908477QA (en) 2019-10-30
US20220088006A1 (en) 2022-03-24
US20220040170A1 (en) 2022-02-10
WO2018170214A1 (en) 2018-09-20
AU2022203369B2 (en) 2024-04-04
US12502385B2 (en) 2025-12-23
AU2022203369A1 (en) 2022-06-09
US20180263972A1 (en) 2018-09-20
NZ757789A (en) 2024-08-30
TWI772382B (zh) 2022-08-01
EA201992168A1 (ru) 2020-03-16
CL2019002629A1 (es) 2020-01-24
KR20230003308A (ko) 2023-01-05
AU2018236336A1 (en) 2019-10-24
JP2020510073A (ja) 2020-04-02
US20200016148A1 (en) 2020-01-16
UA127052C2 (uk) 2023-03-29
MX2019010913A (es) 2020-01-20
EP3596077A1 (en) 2020-01-22
US11813232B2 (en) 2023-11-14
ZA201906326B (en) 2022-12-21
PE20191819A1 (es) 2019-12-27
CO2019011271A2 (es) 2020-02-28
AR111182A1 (es) 2019-06-12

Similar Documents

Publication Publication Date Title
AU2022203369B2 (en) Analogs of deutetrabenazine, their preparation and use
EP3503879B1 (en) Composition comprising (a) a dual agent acting as a 5-ht2a receptor antagonist and cyp2d6 inhibitor and (b) an nmda receptor antagonist for use in the treatment of diseases involving glucose
EA016904B1 (ru) Новый холиновый сокристалл эпалрестата
CN102458435A (zh) 认知衰退的抑制剂
EP1935892B1 (en) Glycyrrhetinic acid-30-amide derivatives and the uses thereof
AU2013259779B2 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
CN108727347A (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
CN100572374C (zh) 葛根素衍生物及其医学用途
CN111943958B (zh) 四氢噻吩并吡啶化合物的b晶型及制法、组合物和应用
CN103421001A (zh) 盐酸小檗碱晶e型物质及制备方法和其药物组合物与用途
HK40018479A (en) Analogs of deutetrabenazine, their preparation and use
CN107434799B (zh) 一种2-氨基-3-取代巯基丙酸酯衍生物，制备方法及其应用
CN104650003A (zh) 一种沃替西汀化合物
BR122014004636B1 (pt) Forma cristalina i de [cloridrato de 4-metilbenzoato de 4-[2-dimetilamino-1-(1-hidroxiciclohexil)etil]fenila], seu uso e seus métodos de preparação, bem como composição farmacêutica
EA044519B1 (ru) Способ получения готовой лекарственной формы деутетрабеназина, содержащая его композиция и способ лечения субъекта, страдающего гиперкинетическим двигательным расстройством
CN107445872B (zh) 一种具有潜在脑靶向性的化合物及其制备方法与应用
RU2783865C2 (ru) Фармацевтические композиции
TW202542164A (zh) 治療過動性運動障礙之化合物
CN105524077A (zh) 银杏内酯k晶k型及制备方法和其组合物与用途
CN105585576A (zh) 银杏内酯k晶l型及制备方法和其组合物与用途
JPH05504765A (ja) 神経学的疾患を治療するための４，４′―〔９ｈ―フルオレン―９―イリデンビス（メチレン）〕ビスピリミジン
CN116396289A (zh) 百香果吲哚类生物碱的制备方法、组合物及在制备治疗抗抑郁症的药物或保健产品中的应用
CN101420947A (zh) 用于非恢复性睡眠的α-2-δ配体
CN109535149A (zh) 甲磺酸替扎尼定化合物及其制备方法和用途
JPH09221426A (ja) 神経細胞保護剤

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: AUSPEX PHARMACEUTICALS LLC (US)

B25G Requested change of headquarter approved

Owner name: AUSPEX PHARMACEUTICALS LLC (US)